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Background
Mycobacterium bovis BCG (BCG) has a number of char-
acteristics that give it great potential to act as a vehicle for
the delivery of recombinant vaccines. However, its success
depends on overcoming the challenges of poor antigen
expression levels and genetic instability. Our studies using
an optimized mycobacterial shuttle vector which utilizes
the Mycobacterium tuberculosis mtrA promoter, induced
upon infection of macrophages, and the M. tuberculosis
19 kDa signal sequence may overcome these issues. We
have used this system to generate a recombinant BCG
(rBCG) expressing HIV-1 subtype C full length Gag or
reverse transcriptase (RT).
Methods
These rBCG vaccines were tested in BALB/c mice in heter-
ologous prime-boost inoculation regimens where the
rBCG was used as a primary vaccine and a matched rMVA
(SAAVI MVA-C) was the booster vaccine.
Results
A low magnitude of ex vivo HIV antigen specific CD8+ T
cells could be detected in spleens 7 days after a single
intraperitoneal inoculation using an ex vivo IFN-γ ELIS-
POT assay. In addition a high magnitude of HIV antigen
specific CD8+ T cells were detected ex vivo in the spleens
of mice primed with rBCG and boosted with SAAVI MVA-
C when both an IFN-γ ELISPOT assay and an H-2Dd MHC
class I pentamer folded with the CD8 peptide to enumer-
ate peptide specific cells was used. These results were
observed for rBCG vaccines constructed using both wild
type BCG Pasteur and an attenuated panthothenic acid
auxotrophic strain.
Conclusion
Thus this rBCG vector system shows strong promise for
development as a priming vaccine to be used in combina-
tion with a heterologous booster vaccine such as a rMVA.
The project was supported by Award Number
R21AI073182 from the National Institute of Allergy And
Infectious Diseases.
from AIDS Vaccine 2009
Paris, France. 19-22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P417 doi:10.1186/1742-4690-6-S3-P417
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P417
© 2009 Stutz et al; licensee BioMed Central Ltd. 